These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1003 related articles for article (PubMed ID: 15052207)

  • 41. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.
    Cobben DC; van der Laan BF; Maas B; Vaalburg W; Suurmeijer AJ; Hoekstra HJ; Jager PL; Elsinga PH
    J Nucl Med; 2004 Feb; 45(2):226-31. PubMed ID: 14960640
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor.
    Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS
    J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.
    Wondergem MJ; Rizvi SN; Jauw Y; Hoekstra OS; Hoetjes N; van de Ven PM; Boellaard R; Chamuleau ME; Cillessen SA; Regelink JC; Zweegman S; Zijlstra JM
    J Nucl Med; 2015 Feb; 56(2):216-21. PubMed ID: 25593118
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation.
    Jungehülsing M; Scheidhauer K; Damm M; Pietrzyk U; Eckel H; Schicha H; Stennert E
    Otolaryngol Head Neck Surg; 2000 Sep; 123(3):294-301. PubMed ID: 10964310
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT.
    Zhao S; Kuge Y; Kohanawa M; Takahashi T; Zhao Y; Yi M; Kanegae K; Seki K; Tamaki N
    J Nucl Med; 2008 Jan; 49(1):135-41. PubMed ID: 18077525
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
    Daniels CE; Lowe VJ; Aubry MC; Allen MS; Jett JR
    Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.
    Whiteford MH; Whiteford HM; Yee LF; Ogunbiyi OA; Dehdashti F; Siegel BA; Birnbaum EH; Fleshman JW; Kodner IJ; Read TE
    Dis Colon Rectum; 2000 Jun; 43(6):759-67; discussion 767-70. PubMed ID: 10859074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules.
    Higashi K; Ueda Y; Sakuma T; Seki H; Oguchi M; Taniguchi M; Taki S; Tonami H; Katsuda S; Yamamoto I
    J Nucl Med; 2001 Oct; 42(10):1489-96. PubMed ID: 11585862
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
    van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
    J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of the ¹⁸f-fluorodeoxyglucose-positron emission tomography scan in the Nederlands Leuvens Longkanker screenings Onderzoek lung cancer screening trial.
    van't Westeinde SC; de Koning HJ; Thunnissen FB; Oudkerk M; Groen HJ; Lammers JW; Weenink C; Vernhout R; Nackaerts K; Mali W; van Klaveren RJ
    J Thorac Oncol; 2011 Oct; 6(10):1704-12. PubMed ID: 21876458
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer.
    Kluge R; Schmidt F; Caca K; Barthel H; Hesse S; Georgi P; Seese A; Huster D; Berr F
    Hepatology; 2001 May; 33(5):1029-35. PubMed ID: 11343227
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck.
    Schmid DT; Stoeckli SJ; Bandhauer F; Huguenin P; Schmid S; von Schulthess GK; Goerres GW
    Laryngoscope; 2003 May; 113(5):888-91. PubMed ID: 12792328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
    Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
    Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).
    Najjar F; Hustinx R; Jerusalem G; Fillet G; Rigo P
    Cancer Biother Radiopharm; 2001 Aug; 16(4):297-304. PubMed ID: 11603000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differentiating benign and malignant pulmonary lesions with FDG-PET.
    Yang SN; Liang JA; Lin FJ; Kwan AS; Kao CH; Shen YY
    Anticancer Res; 2001; 21(6A):4153-7. PubMed ID: 11911310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.